PhaseRx to Present at Upcoming Investor Conferences

SEATTLE, Feb. 27, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA products to correct life-threatening inherited liver diseases in children, today announced that the company will be presenting at the following investor conferences in March 2017. Robert W. Overell, Ph.D., president and chief executive officer, will provide an overview of the company and its development stage programs.

• Cowen and Company 37^th Annual Health Care Conference on Wednesday, March 8 in Boston at 11:20 a.m. EST.
• The 29^th Annual ROTH Conference on Tuesday, March 14 in Dana Point, CA at 5:00 p.m. PDT.

A live audio webcast and replay of the presentations will be available on the investor relations section of PhaseRx's corporate website at www.phaserx.com and will be archived following the presentation for 90 days. Please connect to PhaseRx's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About PhaseRx

PhaseRx is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. PhaseRx's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA Technology^TM platform and is applicable to a significant number of inherited liver diseases. PhaseRx is headquartered in Seattle, WA. For more information, please visit www.phaserx.com.

Contacts: 

Company Contact:
Erin Cox
PhaseRx, Inc.
Head of Investor Relations
[email protected]
206.805.6306

Corporate Communications Contact:
Jason Spark
Canale Communications
Senior Vice President
[email protected]
619-849-6005

Investor Contact:
Robert H. Uhl
Westwicke Partners, LLC
Managing Director
[email protected]
858.356.5932

SOURCE PhaseRx, Inc.

Related Links

http://www.Phaserx.com